IBDEI3IF ; ; 19-NOV-2015
;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
Q:'DIFQR(358.4) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.4,1242,0)
;;=GASTROENTEROLOGY^3^124
;;^UTILITY(U,$J,358.4,1243,0)
;;=GENITORURINARY^4^124
;;^UTILITY(U,$J,358.4,1244,0)
;;=MUSCULOSKELETAL^8^124
;;^UTILITY(U,$J,358.4,1245,0)
;;=NEUROLOGY^9^124
;;^UTILITY(U,$J,358.4,1246,0)
;;=HEMATOLOGY/ONCOLOGY^5^124
;;^UTILITY(U,$J,358.4,1247,0)
;;=INFECTIOUS CONTROL^6^124
;;^UTILITY(U,$J,358.4,1248,0)
;;=SUBSTANCE ABUSE-ALCOHOL^13^124
;;^UTILITY(U,$J,358.4,1249,0)
;;=SUBSTANCE ABUSE-AMPHETAMINE^14^124
;;^UTILITY(U,$J,358.4,1250,0)
;;=SUBSTANCE ABUSE-CANNABIS^15^124
;;^UTILITY(U,$J,358.4,1251,0)
;;=SUBSTANCE ABUSE-COCAINE^16^124
;;^UTILITY(U,$J,358.4,1252,0)
;;=SUBSTANCE ABUSE-HALLUCINOGEN^17^124
;;^UTILITY(U,$J,358.4,1253,0)
;;=SUBSTANCE ABUSE-INHALANT^18^124
;;^UTILITY(U,$J,358.4,1254,0)
;;=SUBSTANCE ABUSE-OPIOID^19^124
;;^UTILITY(U,$J,358.4,1255,0)
;;=SUBSTANCE ABUSE-PSYCHOACTIVE DRUGS^20^124
;;^UTILITY(U,$J,358.4,1256,0)
;;=SUBSTANCE ABUSE-SEDATIVE/HYPNOTIC^21^124
;;^UTILITY(U,$J,358.4,1257,0)
;;=SUBSTANCE ABUSE-TOBACCO^22^124
;;^UTILITY(U,$J,358.4,1258,0)
;;=BIOPSY^1^125
;;^UTILITY(U,$J,358.4,1259,0)
;;=CENTRAL VENOUS ACCESS PROCEDURES^2^125
;;^UTILITY(U,$J,358.4,1260,0)
;;=PERIPHERAL ANGIOPLASTIES^3^125
;;^UTILITY(U,$J,358.4,1261,0)
;;=PROSTHETIC ANEURYSM REPAIR^4^125
;;^UTILITY(U,$J,358.4,1262,0)
;;=VASCULAR INJECTION PROCEDURES^5^125
;;^UTILITY(U,$J,358.4,1263,0)
;;=NEW PATIENT^2^126
;;^UTILITY(U,$J,358.4,1264,0)
;;=ESTABLISHED PATIENT^1^126
;;^UTILITY(U,$J,358.4,1265,0)
;;=CONSULTATIONS^3^126
;;^UTILITY(U,$J,358.4,1266,0)
;;=COMMON VASCULAR DX^1^127
;;^UTILITY(U,$J,358.4,1267,0)
;;=ABDOMINAL PAIN^2^127
;;^UTILITY(U,$J,358.4,1268,0)
;;=AFTERCARE POST SURGERY^3^127
;;^UTILITY(U,$J,358.4,1269,0)
;;=CARDIOVASCULAR^4^127
;;^UTILITY(U,$J,358.4,1270,0)
;;=GENERAL/SIGNS/SYMPTOMS^5^127
;;^UTILITY(U,$J,358.4,1271,0)
;;=HEMATOLOGY/ONCOLOGY^6^127
;;^UTILITY(U,$J,358.4,1272,0)
;;=INFECTIOUS DISEASE^7^127
;;^UTILITY(U,$J,358.4,1273,0)
;;=METASTATIC CANCER SITES^8^127
;;^UTILITY(U,$J,358.4,1274,0)
;;=POST-OP COMPLICATIONS^9^127
;;^UTILITY(U,$J,358.4,1275,0)
;;=RESPIRATORY^10^127
;;^UTILITY(U,$J,358.4,1276,0)
;;=BLIND REHAB SERVICE CODES^1^128
;;^UTILITY(U,$J,358.4,1277,0)
;;=REFRACTION^5^128
;;^UTILITY(U,$J,358.4,1278,0)
;;=GLASSES/CONTACT LENSES^2^128
;;^UTILITY(U,$J,358.4,1279,0)
;;=VISUAL FIELDS^8^128
;;^UTILITY(U,$J,358.4,1280,0)
;;=PHOTOGRAPHY^4^128
;;^UTILITY(U,$J,358.4,1281,0)
;;=LOW VISION^3^128
;;^UTILITY(U,$J,358.4,1282,0)
;;=SPECIAL PROCEDURES^6^128
;;^UTILITY(U,$J,358.4,1283,0)
;;=TEAM MEETINGS/COUNSELING^7^128
;;^UTILITY(U,$J,358.4,1284,0)
;;=ESTABLISHED PATIENT^1^129
;;^UTILITY(U,$J,358.4,1285,0)
;;=NEW PATIENT^2^129
;;^UTILITY(U,$J,358.4,1286,0)
;;=CONSULTATION^3^129
;;^UTILITY(U,$J,358.4,1287,0)
;;=PROLONGED SERVICE^4^129
;;^UTILITY(U,$J,358.4,1288,0)
;;=CONJUNCTIVA/CORNEA^2^130
;;^UTILITY(U,$J,358.4,1289,0)
;;=DIABETES^3^130
;;^UTILITY(U,$J,358.4,1290,0)
;;=GLAUCOMA^4^130
;;^UTILITY(U,$J,358.4,1291,0)
;;=LENS/VITREOUS^5^130
;;^UTILITY(U,$J,358.4,1292,0)
;;=LIDS/LASHES^6^130
;;^UTILITY(U,$J,358.4,1293,0)
;;=MACULA/OPTIC NERVE^7^130
;;^UTILITY(U,$J,358.4,1294,0)
;;=PUPILS/IRIS^8^130
;;^UTILITY(U,$J,358.4,1295,0)
;;=RETINA^9^130
;;^UTILITY(U,$J,358.4,1296,0)
;;=VF HA EOM OTHER^10^130
;;^UTILITY(U,$J,358.4,1297,0)
;;=VA VF^1^130
;;^UTILITY(U,$J,358.4,1298,0)
;;=MFH-NON CLINICIAN VISIT ^2^131
;;^UTILITY(U,$J,358.4,1299,0)
;;=NURSING PROCEDURES^3^131
;;^UTILITY(U,$J,358.4,1300,0)
;;=SPLINTS^4^131
;;^UTILITY(U,$J,358.4,1301,0)
;;=MFH-CLINICIAN VISIT ^1^131
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI3IF 3975 printed Sep 23, 2025@20:25:26 Page 2
IBDEI3IF ; ; 19-NOV-2015
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
+2 if 'DIFQR(358.4)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,99)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.4,1242,0)
+2 ;;=GASTROENTEROLOGY^3^124
+3 ;;^UTILITY(U,$J,358.4,1243,0)
+4 ;;=GENITORURINARY^4^124
+5 ;;^UTILITY(U,$J,358.4,1244,0)
+6 ;;=MUSCULOSKELETAL^8^124
+7 ;;^UTILITY(U,$J,358.4,1245,0)
+8 ;;=NEUROLOGY^9^124
+9 ;;^UTILITY(U,$J,358.4,1246,0)
+10 ;;=HEMATOLOGY/ONCOLOGY^5^124
+11 ;;^UTILITY(U,$J,358.4,1247,0)
+12 ;;=INFECTIOUS CONTROL^6^124
+13 ;;^UTILITY(U,$J,358.4,1248,0)
+14 ;;=SUBSTANCE ABUSE-ALCOHOL^13^124
+15 ;;^UTILITY(U,$J,358.4,1249,0)
+16 ;;=SUBSTANCE ABUSE-AMPHETAMINE^14^124
+17 ;;^UTILITY(U,$J,358.4,1250,0)
+18 ;;=SUBSTANCE ABUSE-CANNABIS^15^124
+19 ;;^UTILITY(U,$J,358.4,1251,0)
+20 ;;=SUBSTANCE ABUSE-COCAINE^16^124
+21 ;;^UTILITY(U,$J,358.4,1252,0)
+22 ;;=SUBSTANCE ABUSE-HALLUCINOGEN^17^124
+23 ;;^UTILITY(U,$J,358.4,1253,0)
+24 ;;=SUBSTANCE ABUSE-INHALANT^18^124
+25 ;;^UTILITY(U,$J,358.4,1254,0)
+26 ;;=SUBSTANCE ABUSE-OPIOID^19^124
+27 ;;^UTILITY(U,$J,358.4,1255,0)
+28 ;;=SUBSTANCE ABUSE-PSYCHOACTIVE DRUGS^20^124
+29 ;;^UTILITY(U,$J,358.4,1256,0)
+30 ;;=SUBSTANCE ABUSE-SEDATIVE/HYPNOTIC^21^124
+31 ;;^UTILITY(U,$J,358.4,1257,0)
+32 ;;=SUBSTANCE ABUSE-TOBACCO^22^124
+33 ;;^UTILITY(U,$J,358.4,1258,0)
+34 ;;=BIOPSY^1^125
+35 ;;^UTILITY(U,$J,358.4,1259,0)
+36 ;;=CENTRAL VENOUS ACCESS PROCEDURES^2^125
+37 ;;^UTILITY(U,$J,358.4,1260,0)
+38 ;;=PERIPHERAL ANGIOPLASTIES^3^125
+39 ;;^UTILITY(U,$J,358.4,1261,0)
+40 ;;=PROSTHETIC ANEURYSM REPAIR^4^125
+41 ;;^UTILITY(U,$J,358.4,1262,0)
+42 ;;=VASCULAR INJECTION PROCEDURES^5^125
+43 ;;^UTILITY(U,$J,358.4,1263,0)
+44 ;;=NEW PATIENT^2^126
+45 ;;^UTILITY(U,$J,358.4,1264,0)
+46 ;;=ESTABLISHED PATIENT^1^126
+47 ;;^UTILITY(U,$J,358.4,1265,0)
+48 ;;=CONSULTATIONS^3^126
+49 ;;^UTILITY(U,$J,358.4,1266,0)
+50 ;;=COMMON VASCULAR DX^1^127
+51 ;;^UTILITY(U,$J,358.4,1267,0)
+52 ;;=ABDOMINAL PAIN^2^127
+53 ;;^UTILITY(U,$J,358.4,1268,0)
+54 ;;=AFTERCARE POST SURGERY^3^127
+55 ;;^UTILITY(U,$J,358.4,1269,0)
+56 ;;=CARDIOVASCULAR^4^127
+57 ;;^UTILITY(U,$J,358.4,1270,0)
+58 ;;=GENERAL/SIGNS/SYMPTOMS^5^127
+59 ;;^UTILITY(U,$J,358.4,1271,0)
+60 ;;=HEMATOLOGY/ONCOLOGY^6^127
+61 ;;^UTILITY(U,$J,358.4,1272,0)
+62 ;;=INFECTIOUS DISEASE^7^127
+63 ;;^UTILITY(U,$J,358.4,1273,0)
+64 ;;=METASTATIC CANCER SITES^8^127
+65 ;;^UTILITY(U,$J,358.4,1274,0)
+66 ;;=POST-OP COMPLICATIONS^9^127
+67 ;;^UTILITY(U,$J,358.4,1275,0)
+68 ;;=RESPIRATORY^10^127
+69 ;;^UTILITY(U,$J,358.4,1276,0)
+70 ;;=BLIND REHAB SERVICE CODES^1^128
+71 ;;^UTILITY(U,$J,358.4,1277,0)
+72 ;;=REFRACTION^5^128
+73 ;;^UTILITY(U,$J,358.4,1278,0)
+74 ;;=GLASSES/CONTACT LENSES^2^128
+75 ;;^UTILITY(U,$J,358.4,1279,0)
+76 ;;=VISUAL FIELDS^8^128
+77 ;;^UTILITY(U,$J,358.4,1280,0)
+78 ;;=PHOTOGRAPHY^4^128
+79 ;;^UTILITY(U,$J,358.4,1281,0)
+80 ;;=LOW VISION^3^128
+81 ;;^UTILITY(U,$J,358.4,1282,0)
+82 ;;=SPECIAL PROCEDURES^6^128
+83 ;;^UTILITY(U,$J,358.4,1283,0)
+84 ;;=TEAM MEETINGS/COUNSELING^7^128
+85 ;;^UTILITY(U,$J,358.4,1284,0)
+86 ;;=ESTABLISHED PATIENT^1^129
+87 ;;^UTILITY(U,$J,358.4,1285,0)
+88 ;;=NEW PATIENT^2^129
+89 ;;^UTILITY(U,$J,358.4,1286,0)
+90 ;;=CONSULTATION^3^129
+91 ;;^UTILITY(U,$J,358.4,1287,0)
+92 ;;=PROLONGED SERVICE^4^129
+93 ;;^UTILITY(U,$J,358.4,1288,0)
+94 ;;=CONJUNCTIVA/CORNEA^2^130
+95 ;;^UTILITY(U,$J,358.4,1289,0)
+96 ;;=DIABETES^3^130
+97 ;;^UTILITY(U,$J,358.4,1290,0)
+98 ;;=GLAUCOMA^4^130
+99 ;;^UTILITY(U,$J,358.4,1291,0)
+100 ;;=LENS/VITREOUS^5^130
+101 ;;^UTILITY(U,$J,358.4,1292,0)
+102 ;;=LIDS/LASHES^6^130
+103 ;;^UTILITY(U,$J,358.4,1293,0)
+104 ;;=MACULA/OPTIC NERVE^7^130
+105 ;;^UTILITY(U,$J,358.4,1294,0)
+106 ;;=PUPILS/IRIS^8^130
+107 ;;^UTILITY(U,$J,358.4,1295,0)
+108 ;;=RETINA^9^130
+109 ;;^UTILITY(U,$J,358.4,1296,0)
+110 ;;=VF HA EOM OTHER^10^130
+111 ;;^UTILITY(U,$J,358.4,1297,0)
+112 ;;=VA VF^1^130
+113 ;;^UTILITY(U,$J,358.4,1298,0)
+114 ;;=MFH-NON CLINICIAN VISIT ^2^131
+115 ;;^UTILITY(U,$J,358.4,1299,0)
+116 ;;=NURSING PROCEDURES^3^131
+117 ;;^UTILITY(U,$J,358.4,1300,0)
+118 ;;=SPLINTS^4^131
+119 ;;^UTILITY(U,$J,358.4,1301,0)
+120 ;;=MFH-CLINICIAN VISIT ^1^131
